

Date: 15th September, 2020

To,
Listing Department,
BSE Limited
Floor 25, PJ Tower
Dalal Street,
Mumbai - 400 001

Script Code: 540359

Sub.: Outcome of the proceedings of the meeting of the Board of Directors of the Company

Dear Sirs,

This is to inform you that the Board of Directors of the Company has, at its meeting held today, inter-alia, considered and approved the Unaudited Financial Results for quarter ended 30th June, 2020. The same has also been reviewed by the Audit Committee in its meeting held today.

A copy of the Statement of Unaudited Financial Results for the quarter ended 30th June, 2020, approved by the Board pursuant to Regulation 33 of the Securities And Exchange Board of India (LODR Regulations, 2015, is enclosed for your reference and record. The meeting was concluded on 6:45 pm.

We would like to submit that M/ s. B A Shah S R Mehta & Co., Statutory Auditors of Company have carried out limited review of Unaudited Financial Results for quarter ended 30th June, 2020 and Board has also taken on record their Limited Review Report on said Results.

Further to inform you that the 26th Annual General Meeting of the Company will be held on Friday, 16th October, 2020 at the registered office of the Company.

Kindly take this on your records.

Thanking you,

Yours faithfully,

For, Parmax Pharma Limited

Yash J. Vora
Yash J. Vora
Company Secretary



Statement of Standalone Unaudited Results for the Quarter ended 30.06.2020

(in Rs.)

Sr. No.	Particulars	Quarter Ended	Preceeding	Corresponding	Previous year
		(30.06.2020)	Quarter ended	Quarter Ended	ended
	(Refer Notes Below)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income from Operations				
	(a) Revenue from operations	22731325	43685011	41134972	209341081
	(b) Other income	115264	500846	187266	977787
	Total income from operations (net) (a+b)	22846589	44185857	41322238	210318868
2	Expenses				
	(a) Cost of materials consumed	24778255	15572077	18841449	97936820
	(b) Purchase of stock-in-trade	0	0	0	0
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-16553620	10573541	4054194	14722662
	(d) Employee benefits expense	8246006	6787577	7015749	29139115
	(e) Finance Costs	913568	912815	148700	1273690
	(f) Depreciation and amortisation expense	4368663	3712230	2168263	10071526
	(g) Other expenses*	11053899	12443145	11948511	49868688
	Total expenses	32806771	50001385	44176866	203012501
3	Profit/(Loss) from operations before exceptional items and tax (1-2)	-9960182	-5815528	-2854628	7306367
4	Exceptional Items	0	0	0	0
5	Profit/ (Loss) before tax (3-4)	-9960182	-5815528	-2854628	7306367
6	Tax expense:				
	(1) Current tax	0	1500000	0	1500000
	(2) Deferred tax	0	1519577	0	1519577
7	Net Profit / (Loss) for the period from continuing operations (5-6)	-9960182	-8835105	-2854628	4286790
8	Profit/(loss) from discontinuing operations				
9	Tax expense of discontinuing operations	0	0	0	0
10	Profit/(loss) from Discontinuing operations (after tax) (8-9)	0	0	0	0
11	Profit (Loss) for the period (7+10)	-9960182	-8835105	-2854628	4286790
12	Other Comprehensive Income	0	0	0	0
13	Total Comprehensive Income for the period (11+12) Comprising Profit (Loss) and Other comprehensive Income for the period)	-9960182	-8835105	-2854628	4286790
14	Paid-up equity share capital (Face Value Rs 10)	37413000	37413000	37413000	37413000
15	Earnings per share (for continuing operation) (of Rs. 10/- each) (not annualised):				
	(a) Basic	-2.66	-2.36	-0.76	1.15
	(b) Diluted	-	-	-	-




Notes:

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 15th September, 2020
 2. The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter ended 30th June, 2020
 3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
 4. Statement of Unaudited Financial Results of the company for the quarter ended 30th June, 2020 in the prescribed format under Schedule III of Companies Act, 2013
 5. The figures for the previous period have been regrouped wherever necessary.
- * The Company has decided to gradually write off its all Preliminary and Pre-operative expenses which are forming the part of Balance Sheet accordingly Company has written off Rs. 9,90,350/- during this quarter under review and it is forming part of Other Expenses.

FOR, PARMAX PHARMA LIMITED

Alkesh Gosalia

Alkesh Gosalia
Managing Director
(Finance and Operations)



Place: Hadamtala (Rajkot)
Date: 15.09.2020

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

Auditor's Limited Review Report On Unaudited Financial Results

To
The Board of Directors,
PARMAX PHARMA LIMITED

We have reviewed the accompanying statement of standalone unaudited financial results of **PARMAX PHARMA LTD** ("the Company") for the quarter ended **30th June 2020** ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on **15th September 2020**. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there



Head Office:
209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Branch Office:
302-Vedant Complex,
7/B Kalpana Society,
C.G.Road, Navrangpura,
AHMEDABAD - 380 009
(GUJARAT)

Electronic Address:
(O) 0281-2468261
(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbshah_31@hotmail.com

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Rajkot

Date : 15.09.2020



For **B. A. SHAH S R MEHTA & Co.**
Chartered Accountants
FRN NO : 128796W

A handwritten signature in blue ink that reads "Malay B. Shah".

MALAY B SHAH

Partner

M. No. 159526

UDIN : 20159526AAAAAP5280

Head Office:

209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Branch Office:

302-Vedant Complex,
7/B Kalpana Society,
C.G.Road, Navrangpura,
AHMEDABAD - 380 009
(GUJARAT)

Electronic Address:

(O) 0281-2468261

(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbsah_31@hotmail.com